NICE’s 5-Year Strategy Signals a More Collaborative Approach.

The UK’s National Institute for Health and Care Excellence (NICE) new health technology assessment manual signals a push towards greater collaboration with the pharmaceutical industry. The new protocol moves away from the previous more oppositional relationship between industry and the agency. NICE’s new directives are built on a “four-pillar” approach.

According to Chris Poole and Keith Tolley of Xcenda, “Key among a series of internal transformations is the establishment of a business development function to identify and secure new sources of income, and to respond to new opportunities to enhance NICE’s impact. This is the clearest practical sign of NICE’s increased willingness for industrial partnership and collaboration. It is no accident that proactive technical engagement into the STA process was introduced in parallel with the decision to begin charging applicants for the privilege; negative decisions are not only bad for patients but also bad for business.”

Learn more about each of the four pillars of NICE’s 5-year strategy by clicking here.

(Source: Xcenda, October 20^th, 2021)